News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
686,259 Results
Type
Article (39079)
Company Profile (279)
Press Release (646901)
Section
Business (203876)
Career Advice (1992)
Deals (35364)
Drug Delivery (86)
Drug Development (80816)
Employer Resources (168)
FDA (16092)
Job Trends (14805)
News (344574)
Policy (32440)
Tag
Academia (2530)
Alliances (49111)
Alzheimer's disease (1239)
Approvals (16025)
Artificial intelligence (141)
Bankruptcy (352)
Best Places to Work (11548)
Biotechnology (200)
Breast cancer (135)
Cancer (1145)
Cardiovascular disease (103)
Career advice (1660)
Cell therapy (240)
Clinical research (64351)
Collaboration (407)
Compensation (211)
COVID-19 (2534)
C-suite (101)
Data (1175)
Diabetes (157)
Diagnostics (6156)
Earnings (84844)
Employer resources (146)
Events (109709)
Executive appointments (326)
FDA (16660)
Funding (372)
Gene therapy (182)
GLP-1 (581)
Government (4327)
Healthcare (18681)
Infectious disease (2620)
Inflammatory bowel disease (108)
Interviews (308)
IPO (16311)
Job creations (3624)
Job search strategy (1417)
Layoffs (414)
Legal (7854)
Lung cancer (174)
Manufacturing (179)
Medical device (13187)
Medtech (13192)
Mergers & acquisitions (19153)
Metabolic disorders (410)
Neuroscience (1527)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1539)
Obesity (234)
Opinion (179)
Patents (108)
People (56313)
Phase I (19993)
Phase II (28340)
Phase III (21133)
Pipeline (475)
Postmarket research (2555)
Preclinical (8505)
Radiopharmaceuticals (236)
Rare diseases (228)
Real estate (5890)
Regulatory (21561)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1335)
Startups (3562)
United States (13939)
Vaccines (553)
Weight loss (169)
Date
Today (108)
Last 7 days (381)
Last 30 days (3263)
Last 365 days (35503)
2024 (33365)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54088)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (193)
Asia (37170)
Australia (6065)
California (3449)
Canada (1336)
China (268)
Colorado (151)
Connecticut (159)
Europe (79583)
Florida (481)
Georgia (122)
Illinois (351)
Indiana (204)
Kansas (96)
Maryland (595)
Massachusetts (2711)
Michigan (160)
Minnesota (277)
New Jersey (992)
New York (996)
North Carolina (714)
Northern California (1539)
Ohio (142)
Pennsylvania (866)
South America (1091)
Southern California (1335)
Texas (495)
Utah (92)
Washington State (371)
686,259 Results for "nanoviricides inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
NanoViricides, Inc. reports that it has engaged Aagami, Inc. for business development, specifically to seek licensing and partnering opportunities for our assets and platform technology.
May 23, 2024
·
9 min read
Business
NanoViricides Has Filed its Quarterly Report - May 15, 2024
NanoViricides, Inc. reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending March 31, 2024 with the Securities and Exchange Commission on Tuesday, May 14, 2024.
May 15, 2024
·
12 min read
Press Releases
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
November 15, 2024
·
11 min read
NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
NanoViricides, Inc., a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its current assets and plans towards becoming a successful pharmaceutical company intending to revolutionize the treatment of viral infections.
July 1, 2024
·
9 min read
Press Releases
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
October 8, 2024
·
9 min read
Drug Development
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon.
April 30, 2024
·
9 min read
Press Releases
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
November 4, 2024
·
7 min read
Pharm Country
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
NanoViricides, Inc., a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum antiviral NV-387 could be an important weapon against bird flu H5N1 viruses.
June 24, 2024
·
8 min read
Pharm Country
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, announces that Anil R. Diwan, Ph.D., the Company’s President and Executive Chairman, will be attending the EF Hutton Annual Global Conference, which will be held at The Plaza Hotel in New York, NY on Wednesday, May 15, 2024.
May 10, 2024
·
8 min read
Press Releases
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
October 1, 2024
·
11 min read
1 of 68,626
Next
